Edgar G. Engleman, MD, Professor, Departments of Pathology and Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine
Research Description: Dr. Engleman’s research has focused on studies of the role of different leukocyte subpopulations in disease pathogenesis, including autoimmune diseases, metabolic diseases, graft versus host disease and transplantation tolerance. Several years ago, his group discovered an unexpected increase in the frequency of T helper 1 cells in the adipose tissue of diet induced obese (DIO) mice, and proved that such cells play a critical role in the development of insulin resistance in this model. Subsequently, his group found that B cells and the antibodies they produce also play a pathogenic role in this disorder. Both of these populations overwhelm regulatory T and B cells, which normally help maintain a state of insulin sensitivity. These findings have led to a new way of thinking in the field of metabolism that may ultimately lead to important new diagnostic, prophylactic and therapeutic modalities for insulin resistance and type 2 diabetes.
Selected relevant publications (Stanford DRC members in BOLD):
1. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. 2011. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nature Med. 17:610-617.
2. McLaughlin T, Liu LF, Lamendola C, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Shen L, Engleman E. 2014. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 34:2637-2643. Epub 2014 Oct 23. [PMCID: PMC4445971]
3. Shen L, Chng MHY, Alonso MN, Yuan R, Winer DA, Engleman EG. 2015. B-1a lymphocytes attenuate insulin resistance. Diabetes 64:593-603.
4. Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo X, Lei H, Luk C, Shi S, Surendra A, Copeland J, Ahn J, Prescott D, Rasmussen B, Chng M, Engleman EG, Girardin S, Lam TKT, Croitoru K, Dunn S, Philpott DJ, Guttman DS, Woo M, Winer S, Winer DA. 2015. Regulation of oesity-related insulin resistance with gut anti-inflammatory agents. Cell Metabolism 21:527–542.
5. Liu LF, Kodama K, Wei K, Tolentino LL, Choi O, Engleman EG, Butte AJ, McLaughlin T. 2015. The receptor CD44 is associated with insulin resistance, adipose tissue inflammation, and macrophage activation in obese humans. Diabetologia 58:1579-1586. doi: 10.1007/s00125-015-3603-y.
6. Revelo XS, Ghazarian M, Chng MH, Luck H, Kim JH, Zeng K, Shi SY, Tsai S, Lei H, Kenkel J, Liu CL, Tangsombatvisit S, Tsui H, Sima C, Xiao C, Shen L, Li X, Jin T, Lewis GF, Woo M, Utz PJ, Glogauer M, Engleman E, Winer S, Winer DA. 2016. Nucleic acid-targeting pathways promote inflammation in obesity-related insulin resistance. Cell Reports 16:717-730. doi: 10.1016/j.celrep.2016.06.024. Epub 2016 Jun 30.]
7. McLaughlin T, Ackerman SE, Shen L, Engleman E. 2017. Role of innate and adaptive immunity in obesity-associated insulin resistance and type 2 diabetes. J. Clin. Invest. In Press.